WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the second quarter of 2007. The Company reported total revenues of $15.9 million in the second quarter of 2007, compared to $4.6 million in total revenues in the second quarter of 2006, prior to the acquisition of ANTARA® (fenofibrate) capsules. During the second quarter of 2007, the Company recorded approximately $14.1 million in revenue from ANTARA and $1.8 million in revenues related to FACTIVE® (gemifloxacin mesylate) tablets.
